Blockade of EGFR signaling through small-molecule tyrosine kinase inhibitors (TKI) or targeted biologics has thus far been unsuccessful in GBM treatment, which contrasts with other EGFR-driven neoplasms, such as non-small cell lung cancer (NSCLC) [50]. This evidence concerns the gene EGFR and glioblastoma.